Shortly after submission of this manuscript, a recent large multicenter retrospective cohort study integrating genetic and clinical data from 4,746 PTC patients examined whether incorporating BRAF V600E and TERT promoter mutations could improve the prognostic accuracy of the AJCC/TNM staging system for thyroid cancer–specific mortality (19). The gene discussed is BRAF; the disease is thyroid gland carcinoma.